Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized placebo-controlled neoadjuvant chemotherapy study of nintedanib with gemcitabine and cisplatin in muscle-invasive bladder cancer
2012-004895-21Phase 2Unknown
- Sponsor
- The Clatterbridge Cancer Centre NHS Foundation Trust
- Start
- Dec 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in muscle-invasive bladder carcinoma (MIBC) comparing Nintedanib + gemcitabine + cisplatin with Placebo + gemcitabine + cisplatin (2 arms). Primary endpoint: Pathological complete response. Status: unknown.
02
Drugs
nintedanib
03
Conditions
muscle-invasive bladder carcinoma (MIBC)
Beyond the preview
Go deeper on 2012-004895-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-004895-21.